Predictors of Responsiveness to GLP-1 Receptor Agonists in Insulin-Treated Patients with Type 2 Diabetes.
Journal
Journal of diabetes research
ISSN: 2314-6753
Titre abrégé: J Diabetes Res
Pays: England
ID NLM: 101605237
Informations de publication
Date de publication:
2023
2023
Historique:
received:
20
02
2023
revised:
13
06
2023
accepted:
31
07
2023
medline:
18
8
2023
pubmed:
17
8
2023
entrez:
17
8
2023
Statut:
epublish
Résumé
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are potent antihyperglycemic agents with beneficial effects on weight, cardiovascular, and renal outcomes. Physicians lack guidance as to which patients with insulin-requiring type 2 diabetes will respond best to GLP-1 RAs with respect to glycemic control, insulin dose reduction, and weight loss. This study evaluated the efficacy of GLP-1 RAs in patients with type 2 diabetes on insulin and patient factors that may predict a beneficial clinical response. Adults with type 2 diabetes treated with insulin who had a GLP-1 RA added to their regimen were evaluated retrospectively. Baseline parameters and outcomes at 3, 6, and 12 months were collected. Among the 81 patients included, there was a mean reduction in hemoglobin A1C of 0.94% (SD, 0.26; The addition of a GLP-1 RA reduced HbA1C, weight, and insulin requirements in this cohort of patients with type 2 diabetes on insulin. BMI, baseline insulin dose, and diabetes duration did not predict response. A C-peptide level ≥ 0.8 ng/ml predicted a beneficial response after 3 months of therapy.
Sections du résumé
Background
UNASSIGNED
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are potent antihyperglycemic agents with beneficial effects on weight, cardiovascular, and renal outcomes. Physicians lack guidance as to which patients with insulin-requiring type 2 diabetes will respond best to GLP-1 RAs with respect to glycemic control, insulin dose reduction, and weight loss. This study evaluated the efficacy of GLP-1 RAs in patients with type 2 diabetes on insulin and patient factors that may predict a beneficial clinical response.
Methods
UNASSIGNED
Adults with type 2 diabetes treated with insulin who had a GLP-1 RA added to their regimen were evaluated retrospectively. Baseline parameters and outcomes at 3, 6, and 12 months were collected.
Results
UNASSIGNED
Among the 81 patients included, there was a mean reduction in hemoglobin A1C of 0.94% (SD, 0.26;
Conclusions
UNASSIGNED
The addition of a GLP-1 RA reduced HbA1C, weight, and insulin requirements in this cohort of patients with type 2 diabetes on insulin. BMI, baseline insulin dose, and diabetes duration did not predict response. A C-peptide level ≥ 0.8 ng/ml predicted a beneficial response after 3 months of therapy.
Identifiants
pubmed: 37589043
doi: 10.1155/2023/9972132
pmc: PMC10427225
doi:
Substances chimiques
C-Peptide
0
Glucagon-Like Peptide-1 Receptor
0
Glycated Hemoglobin
0
Insulin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9972132Informations de copyright
Copyright © 2023 Colleen Gavigan and Thomas Donner.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest.
Références
Diabetes Obes Metab. 2022 Oct;24(10):1912-1926
pubmed: 35676794
Diabet Med. 2013 Jul;30(7):803-17
pubmed: 23413806
Diabetes Care. 2020 Oct;43(10):2509-2518
pubmed: 32694215
Diabetologia. 1999 Apr;42(4):406-12
pubmed: 10230643
Int J Environ Res Public Health. 2019 Dec 27;17(1):
pubmed: 31892206
J Diabetes Res. 2016;2016:4509603
pubmed: 27882332
N Engl J Med. 2016 Jul 28;375(4):311-22
pubmed: 27295427
Diabet Med. 1994 Dec;11(10):953-60
pubmed: 7895460
Diabetes Care. 2012 May;35(5):955-8
pubmed: 22432107
J Korean Med Sci. 2013 Jun;28(6):881-7
pubmed: 23772153
Diabetes Metab J. 2011 Apr;35(2):159-65
pubmed: 21738898
Diabetes Res Clin Pract. 2005 Jan;67(1):43-52
pubmed: 15620433
Endocr Pract. 1997 Mar-Apr;3(2):73-6
pubmed: 15251479
N Engl J Med. 2016 Nov 10;375(19):1834-1844
pubmed: 27633186
Cell Metab. 2006 Mar;3(3):153-65
pubmed: 16517403
Diabetes Care. 2014 Aug;37(8):2317-25
pubmed: 24898300
Diabetes Care. 2021 Feb;44(2):390-398
pubmed: 33303639
Diabetes Care. 2016 Feb;39(2):250-7
pubmed: 26242184
Klin Med (Mosk). 2014;92(10):52-9
pubmed: 25782322
J Diabetes Complications. 2013 Jan-Feb;27(1):87-91
pubmed: 22863615
J Diabetes Res. 2019 Mar 03;2019:1365162
pubmed: 30944827
J Diabetes Investig. 2014 Sep;5(5):554-62
pubmed: 25411624
Diabet Med. 2016 Nov;33(11):1554-1558
pubmed: 27100275
Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-785
pubmed: 31422062
Lancet. 2019 Jul 13;394(10193):121-130
pubmed: 31189511
Diabetes Obes Metab. 2003 May;5(3):163-70
pubmed: 12681023
Eur J Clin Pharmacol. 1993;44(2):107-12
pubmed: 8453955
J Diabetes Res. 2015;2015:162718
pubmed: 25688374